Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.Original Article
In another blockbuster cancer deal, Merck lays out up to $5.8B for half of Eisai’s Lenvima
